Holen Sie sich die Stockscreener-App
1.15
1.32%
0.015
Handel nachbörslich:
1.13
-0.02
-1.74%
Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten
Tiziana Life Sciences Ltd (TLSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Tiziana Life Sciences (TLSA) insider adds 42,357 shares via Panetta Partners - Stock Titan
Tiziana Life Sciences Ltd (TLSA) director adds 15,000 shares in open-market buy - Stock Titan
Tiziana Life Sciences CEO & Executive Director Acquires 18% More Stock - simplywall.st
Tiziana Life Sciences (TLSA) CEO Boosts Stake Amid Unprofitable Operations and Low Valuation - GuruFocus
TLSA | Tiziana Life Sciences Ltd. Insider Trading - Quiver Quantitative
Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases 83,807 Shares of Stock - MarketBeat
Ivor Elrifi Acquires 237,616 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock - marketbeat.com
Tiziana Life Sciences : Announces Purchase of Shares by Chief Executive Officer - marketscreener.com
Tiziana Life Sciences (Nasdaq: TLSA) CEO boosts stake with 321,423-share buy - Stock Titan
Tiziana Life Sciences announces CEO share purchase - Proactive financial news
Tiziana Life Sciences (TLSA) CEO buys 321,423 shares via trust - Stock Titan
Tiziana Life Sciences (NASDAQ:TLSA) CEO Ivor Elrifi Purchases 667,000 Shares - MarketBeat
Tiziana Life Sciences (TLSA) CEO buys 667,000 new shares - Stock Titan
Tiziana Life Sciences CEO Boosts Stake as Lead MS Therapy Progresses - The Globe and Mail
Tiziana Life Sciences (TLSA) CEO Boosts Stake Amid Positive MS T - GuruFocus
Tiziana Life Sciences (NASDAQ: TLSA) CEO purchases 667,000 shares at $1 - Stock Titan
Tiziana CEO adds to holdings - Proactive financial news
Tiziana Life Sciences (TLSA) Slips 5.8% to $0.97, Approaches Key Support at $0.92Reversal Setup Alerts - dars.gov.et
Tiziana Life Sciences Ltd Revenue Breakdown – NASDAQ:TLSA - TradingView
Small cap wrap: Medicus Pharma, Tiziana Life Sciences, Namibia Critical Metals... - Proactive financial news
Tiziana Life Sciences Posts Reproducible PET Evidence of Reduced Brain Inflammation in Third MSA Patient - TipRanks
Tiziana Life Sciences Reports Reduced Neuroinflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab - Quiver Quantitative
Reduced brain inflammation seen in MSA trial at Tiziana (Nasdaq: TLSA) - Stock Titan
Tiziana Reports Reduction in Brain Inflammation in Third - GlobeNewswire
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab - The Manila Times
Tiziana Life Sciences Ltd (TLSA) Institutional Confidence - TradingKey
Tiziana Life Sciences Ltd (TLSA) Cash Flow - TradingKey
Tiziana Life Sciences Ltd (TLSA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tiziana Life Sciences Ltd (TLSA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TLSA|Tiziana Life Sciences Ltd|Price:0.985|Chg%:-0.005 - TradingKey
Tiziana Life Sciences Ltd (TLSA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tiziana Life Sciences Ltd (TLSA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tiziana Life Sciences Ltd (TLSA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tiziana Life Sciences Ltd (TLSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TLSA|Tiziana Life Sciences Ltd|Price:0.910|Chg%:+0.018 - TradingKey
TradingKey - TradingKey
Tiziana Life Sciences Ltd. Revenue Breakdown – FWB:0RP - TradingView
Tiziana Life Sciences Ltd. Revenue Breakdown – GETTEX:0RP - TradingView
Tiziana Life Sciences (TLSA) insider awarded 42,357 shares of common stock - Stock Titan
Tiziana Life Sciences Chairman Boosts Stake to Nearly 35% in July Share Purchase - The Globe and Mail
Tiziana Life Sciences (TLSA) Executive Chairman Increases Stake - GuruFocus
Tiziana Life Sciences says executive chairman increased stake with share purchase - Proactive financial news
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman - The Manila Times
Tiziana Life Sciences (Nasdaq: TLSA) chair lifts holding to 34.93% stake - Stock Titan
Tiziana Life Sciences Ltd. - Via Ritzau
Tiziana Life Sciences (TLSA) Sees Pullback as Shares Test Key Support ZoneRetail Driven Moves - dars.gov.et
symbol__ Stock Quote Price and Forecast - CNN
Keeren Rameshchandra Shah Net Worth (2026) - GuruFocus
Tiziana Life Sciences (TLSA) Slips 2.73% as Stock Tests Key Support LevelsStock News - dars.gov.et
Tiziana Life Sciences (NASDAQ:TLSA) Rating Increased to Hold at Zacks Research - MarketBeat
Tiziana Life Sciences (NASDAQ:TLSA) Shares Up 8.1%What's Next? - MarketBeat
Enterprise value to EBITDA forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA - TradingView
Price to book forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA - TradingView
Price to sales forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA - TradingView
Enterprise value to revenue forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA - TradingView
Enterprise value to EBIT forward of Tiziana Life Sciences Ltd – NASDAQ:TLSA - TradingView
Tiziana Life Sciences Ltd. Actuals & Estimates (DUS:0RP) - TradingView
Tiziana Life Sciences Ltd. Actuals & Estimates (NASDAQ:TLSA) - TradingView
Tiziana Life Sciences Ltd. Actuals & Estimates (FWB:0RP) - TradingView
TLSA Forecast — Price Target — Prediction for 2027 - TradingView
Tiziana Life Sciences Ltd. Actuals & Estimates (TRADEGATE:0RP) - TradingView
Small cap wrap: Power Metallic Mines, Tiziana Life Sciences, Fox Tungsten, American Resources… - Proactive financial news
0RP Forecast — Price Target — Prediction for 2027 - TradingView
Could Intranasal Innovation Shape the Future of Multiple Sclerosis Care? - Kalkine Media
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial - Yahoo! Finance Canada
Tiziana Life Sciences (TLSA) Advances Clinical Trial for Multiple Sclerosis Treatment - GuruFocus
Tiziana Life Sciences Doses Last Patient in Phase 2 Trial of Potential Multiple Sclerosis Treatment - Moomoo
Tiziana (Nasdaq: TLSA) completes enrollment in Phase 2a INFORM-MS study - Stock Titan
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):